FTSE 100 movers: Glaxo jumps on results; Meggitt tumbles after profit warning
28th Oct 2015 13:10
(ShareCast News) - London's FTSE 100 index was up 0.8% to 6,415.65 at 1400 GMT as investors awaited the Federal Reserve's policy announcement, which is due after the European close. Pharmaceuticals giant GlaxoSmithKline was the standout gainer after its third-quarter revenue and core earnings per sh
Read moreGlaxoSmithKline's consumer strength lifts third-quarter results above forecast
28th Oct 2015 12:05
(ShareCast News) - GlaxoSmithKline posted third-quarter results with revenue and core earnings per share beating market expectations, though management held full year guidance steady. Revenues rose 11% to £6.13bn to beat consensus forecasts of £6.07bn and core EPS declines 13% at constant exchange r
Read moreWednesday preview: Federal Reserve announces interest rate decision
27th Oct 2015 12:56
(ShareCast News) - The Federal Reserve is expected to stay put on interest rates when it makes its policy announcement on Wednesday. Economists predict the central bank will keep rates at 0.25% amid low inflation and concerns about the risks arising from a slowdown in emerging markets. "While expec
Read moreGlaxo gets good results from shingles and asthma treatments; heart drug disappoints
27th Oct 2015 11:20
(ShareCast News) - GlaxoSmithKline has received positive results from studies on its asthma treatment, Advair Diskus and Shingrix, its treatment for shingles, but the results of a study on its losmapimod drug for heart treatment were disappointing. The pharmaceuticals giant said its LABA safety stud
Read moreGlaxoSmithKline's Volibris drug receives positive recommendation
23rd Oct 2015 12:34
(ShareCast News) - A committee of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Volibris drug be approved for use in combination treatment for patients with pulmonary arterial hypertension. The Committee for Medicinal Products for Human Use (CHMP) announced the formal recomme
Read moreGlaxoSmithKline announces positive results from Incruse Ellipsa studies
20th Oct 2015 13:22
(ShareCast News) - GlaxoSmithKline announced positive results from two studies directly comparing the efficacy and safety of its Incruse Ellipta treatment for chronic obstructive pulmonary disease to two existing treatments. The pharmaceuticals giant said that results from a randomised, blinded stud
Read moreBroker tips: Jupiter Fund Management, Ladbrokes, GSK
13th Oct 2015 16:41
(ShareCast News) - RBC Capital Markets has upgraded Jupiter Fund Management as it believes current forecasts underestimate the group's inflows and capital returns. After Monday's trading update, RBC's new 'outperform' rating, up from the previous 'sector perform', is accompanied by a 3% increase in
Read moreLondon close: Stocks close lower on UK deflation, weak Chinese trade data
13th Oct 2015 16:12
(ShareCast News) - The FTSE 100 ended down 28.90 points to 6,342.28 on Tuesday as September data showed the UK experienced deflation and China's exports and imports declined. The Office for National Statistics said the UK consumer price index fell 0.1% year-on-year last month, compared to analysts'
Read moreFTSE 100 movers: SAB surges on AB InBev agreement; Royal Mail slumps
13th Oct 2015 13:59
(ShareCast News) - London's FTSE 100 was down 1.1% by mid afternoon at 6,304.21 as uninspiring Chinese trade figures and UK inflation data weighed on investors' minds. London-listed brewer SABMiller surged after it agreed in principle to a possible £44 per share takeover offer from Belgium-based Anh
Read moreJPMorgan ups Glaxo to 'neutral', says consensus now looks achievable
13th Oct 2015 12:24
(ShareCast News) - JPMorgan Cazenove upgraded GlaxoSmithKline to 'neutral' from 'underweight' and lifted the price target to 1,370p from 1,320p. The bank noted that medium-term consensus earnings per share estimates have fallen 15-18% year-to-date and expectations now look achievable, with downgrade
Read moreTuesday broker round-up
13th Oct 2015 09:49
(ShareCast News) - Ladbrokes: Citigroup upgrades to neutral, raises target price to 110.00p. Jupiter Fund Management: RBC Capital Markets upgrades to outperform, bumps up target price to 475.00p. Jefferies reiterates to buy, lifts target price to 493.00p. Glaxosmithkline: JP Morgan Cazenove upgrade
Read moreGlaxo makes European application for antiseptic gel
12th Oct 2015 08:16
(ShareCast News) - GlaxoSmithKline has submitted a regulatory application to the European Medicines Agency for its antiseptic chlorhexidine gel for the prevention of umbilical cord infections in newborn babies. Glaxo said the EMA has granted the application accelerated assessment, a process open to
Read moreGlencore director backs company to the tune of nearly half a million pounds
1st Oct 2015 16:31
(ShareCast News) - Glencore nearly bounced to pre-slump levels on Thursday, and director John Mack showed investors he's still backing the mining company. Shares in the FTSE 100-listed company dropped dramatically on Monday after Investec warned the stock holds little value for shareholders. But Jo
Read moreGlaxoSmithKline to file application for COPD drug in Japan
24th Sep 2015 08:24
(ShareCast News) - GlaxoSmithKline and Theravance intend to file a supplemental new drug application with the Japanese regulatory authority in the first quarter of 2016 for Relvar Ellipta, which is used for the treatment of chronic obstructive pulmonary disease. The pharmaceuticals company said the
Read moreFTSE 100 movers: Miners and financials drive third successive uptick
9th Sep 2015 14:55
(ShareCast News) - The FTSE 100 index was higher for the third day of the week, led by miners and financials stocks. Diversified miner Anglo American was the leader of the pack with an hour to go on Wednesday as it confirmed the sale of loss-making Rustenberg mining and concentrating operations to S
Read more